Literature DB >> 8960725

Painful vasculitic neuropathy in HIV-1 infection: relief of pain with prednisone therapy.

W G Bradley1, A Verma.   

Abstract

Painful distal sensory polyneuropathy (DSP) is the most common peripheral neuropathy in patients with human immunodeficiency virus-1 (HIV-1) infection. There is no specific therapy for DSP, and nonspecific treatment with pain blockers and narcotic agents generally fails to adequately control the symptoms. We report two patients who had subacute painful neuropathy in the B2 (formerly AIDS-related complex [ARC]) stage of HIV-1 infection. Neurophysiologic studies revealed predominantly axonal sensorimotor neuropathy. Sural nerve biopsy in both cases showed a necrotizing vasculitis. Treatment with corticosteroids resulted in rapid relief of pain, followed by arrest of the neuropathic process. Although not previously emphasized, vasculitic neuropathy must be considered among the treatable causes of painful sensory neuropathy in HIV-1-infected individuals.

Entities:  

Mesh:

Year:  1996        PMID: 8960725     DOI: 10.1212/wnl.47.6.1446

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

Review 1.  Diagnosis of acute neuropathies.

Authors:  Clarissa Crone; Christian Krarup
Journal:  J Neurol       Date:  2007-09-21       Impact factor: 4.849

Review 2.  Processing of nerve biopsies: a practical guide for neuropathologists.

Authors:  Joachim Weis; Sebastian Brandner; Martin Lammens; Claudia Sommer; Jean-Michel Vallat
Journal:  Clin Neuropathol       Date:  2012 Jan-Feb       Impact factor: 1.368

Review 3.  Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Tudor J C Phillips; Catherine L Cherry; Sarah Cox; Sarah J Marshall; Andrew S C Rice
Journal:  PLoS One       Date:  2010-12-28       Impact factor: 3.240

4.  Therapy for vasculitic neuropathies.

Authors:  Kenneth C Gorson
Journal:  Curr Treat Options Neurol       Date:  2006-03       Impact factor: 3.972

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.